EICHOR
● Recruiting
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
Condition: SCLC, Extensive Stage · Sponsor: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
About this study
Oncolytic virus product named Olvi-Vec combined with Platinum plus Etoposide in patients with late phase SCLC
This description comes directly from the study's public registry record.
Talk to the study team
Hannah Chen · +8613801955339 · hannah.chen@newsoara.com
Helena zhu · helena.zhu@newsoara.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Zhejiang Provincial People's Hospital | Hangzhou, China | Recruiting |
| Shanghai chest hospital | Shanghai, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07136285